Friday's Top 10 Articles, Videos on TheStreet
NEW YORK (TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.
Biotech Stock Mailbag: Vivus, Chelsea, BioCryst
Adam Feuerstein
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
General Electric's 'Cash Gusher' Will Lift Shares: Analyst
Dan Freed
The company's financial arm could pay $27 billion in dividends.
The 5 Dumbest Things on Wall Street: Feb. 17
Gregg Greenberg
Apple's China Troubles; MSG's Lin-sanity; Avon Gets Dinged; Energy Conversion Convulsion; Yahoo! Channels Charlie.
Antoine Gara
Watch for a bank ratings cut to damper 2012 share gains of the largest U.S. banks. The Next Big Thing in Biotech: Vivus, Chelsea
Adam Feuerstein
Senior columnist Adam Feuerstein explains why Vivus and Chelsea Therapeutics are the next big things in biotech. Gilead Suffers First Hep C Drug Setback
Adam Feuerstein
Gilead's GS-7977 fails to cure hard-to-treat hepatitis C patients, showing the wonder drug has flaws. Stocks Mixed as Investors Eye Greek Rescue Package
Andrea Tse
U.S. stocks were mixed Friday as investors digested greater confidence about a Greek bailout and varied national inflation reads. Can Apple Investors Sue For a Dividend?
Chris Ciaccia
Apple had close to $100 billion in cash on its books at the end of the first quarter. Do investors have a legal right to it? 15 Hot, Highly Rated Technology Stocks of 2012 (Update 1)
Frank Byrt
These are proven gainers with a measure of safety. Wells Fargo Is a Less Risky Bank of America
Philip van Doorn
In contrast to Bank of America's recent downgrade parade, Sterne Agee analyst Todd Hagerman on Friday raised his earnings estimate and price target for Wells Fargo, saying investors could see "an upside earnings surprise in 2012."
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
